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The problem in this investigation was to determine 
whether or not serial quantitative determinations of the 
circulating eosinophil leucocytes could be used as an 
index in following the clinical course of reactivated 
prostatic carcinoma.
In patients that showed reactivation of their dis­
ease, the eosinophil leucocyte count average approximately 
one-third less than that of the patients that were con­
trolled by anti-androgenic therapy. However, when indi­
vidual counts in the two groups of patients were compared 
a great degree of overlap was noted; non-reactivated 
patients having eosinophil leucocyte counts, in many 
instances that were in the range of the counts observed 
in patients undergoing relapse. Low values were also 
observed in a group of clinically deteriorating patients 
with actively growing malignancies other than carcinoma 
of the prostate.
Although acute adrenal hyperfunction results in a de­
crease in the number of circulating eosinophils, it is felt 
by most investigators at the present time that the absolute 
level of eosinophil leucocytes in the blood at any given 
time does not accurately reflect the state of adrenal corti­
cal activity. If the suggestive depression of the eosino­
phil count in patients with reactivated carcinoma of the 
prostate is significant, it may indicate only an adrenal 
response to "non-specific" stress rather than being a 
specific measure of adrenal hyperactivity with resultant 
androgen stimulus to the tumor. From the results of this 
study it would seem that the eosinophil leucocyte count 
cannot be used in following the clinical course of re­
activated prostatic carcinoma patients.
This abstract of about 250 words is approved as to form 
and content. I recommend its publication.
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INTRODUCTION
Early in history man observed that the 
testis controlled the development and state of 
the secondary sexual organs. Farmers used this 
information in the production of capons. Cas­
tration of bulls and other animals was found 
to be useful. Certain Asiatics took advant­
age of the suppression of the secondary sex­
ual characteristics and sexual drive by cas­
trating prepuberal boys to supply eunuchs for 
their harems.^
In summarizing the early histroy of the 
scientific study of the prostate and its re-
lationship to the testes, White stated:
i
"John Hunter observed that in the mole the 
prostate gland in winter was 'hardly discern­
ible, but in the spring becomes very large and 
filled with mucus’ . Owen confirms this and 
adds that ’ the prostate gland in the mole be­
gins to increase in February and acquires an 
enormous size and conceals the urinary bladder
2toward the end of March*. Owen found similar changes in 
the prostate of the hedge hog. Griffiths examined for 
himself the generative organs of the mole and the hedge 
hog in and out of the rut ting season, and found the above 
observations to be correct. He made a number of sections 
of the gland in the quiescent state, and others during 
the period of sexual activity. During the former period 
he found it composed of a few tubules lined by flattened 
and small epithelial cells, undoubtedly functionless, as 
regards the production of any secretion, but possessing 
the power of reproducing glandular epithelial cells at 
the appropriate period. Precisely similar phenomena were 
observed in the seminiferous tubules of the testicle, and 
in both the changes were preceded by an increased vascu­
larity of the whole tract, determining an increased growth
’4 ^
of all the glands and parts concerned in generation.
" As to the effects of castration, Hunter again was 
the first to note that while the prostate of the perfect 
bull is soft and bulky, that of the castrated animal is 
small, flabby, tough and ligamentous.”
This knowledge of a general biological principle 
was put to little scientific use in the treatment of 
disease in man until the end of the nineteenth ceatury.
White, after noting a decrease in the size of the pros­
tate of castrated dogs--first the glandular and then the 
muscular elements—when the dog was sacrificed, accumu­
lated 111 cases of castration for hypertrophy of tbe human 
prostate. At that time no differentiation was made be­
tween cancer of the prostate and benign hypertrophy. The 
evaluation of the results became so controversial that it 
is not possible at the present time to interpret these with 
any accuracy.
Orchiectomy had been extensively practiced in the 
treatment of non-cancerous prostatism but Young®® first 
described its employment in the treatment of prostatic 
carcinoma. Young’ s experience was limited to two cases 
and the results were negative.
Strohm5® in 1935 reported that placental blood in­
jected intramuscularly acted as a great boon to pale old 
men suffering with malignancy of the prostate gland. 
Counsellor9 and lunger,45 independently, reported their 
experiences in the treatment of cancer of the prostate 
with irradiation of the testicles. In 1941 research in 
prostatic cancer received great impetus from the dis­
covery by Huggins and his associates,51■, 3 3 , that 
remarkable regression occurred clinically in the primary 
neoplasm and its metastases, after castration or admin-
3.
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istration of estrogens. These findings were subsequently 
verified by others.26 Wide acceptance of the thesis that 
androgens must be removed or neutralized led Huggins and 
his associates, as well as others, to search for sources 
of androgens in organs other than the testes and for ways 
of removing or neutralizing them.
Since the adrenal glands produce some androgenically 
active compounds, many virologists believe that, or wonder 
if, reactivation of prostatic cancer after periods of con­
trol by castration and estrogen therapy may be due to an 
increased androgen production by the adrenals. As acute 
adrenal hyperfunction causes a fall in the number of 
circulating eosinophils, it seemed possible that an in­
crease in adrenal function, if such be responsible for 
the reactivation of prostatic carcinoma after castration 
and estrogen therapy, might be reflected in the eosinophil 
count. The question raised is, can the eosinophil count 
be used as one of the indices in following the growth of 
reactivated prostatic cancer in much the same way as the 
level of the serum acid phosphatase is used In many casesj 
hence the purpose of this investigation. Before presenting 
the results of enumeration of circulating eosinophils in 
patients with prostatic cancer, I would like to review the 
endocrine factors that are found In association with car­
cinoma of the prostate.
A REVIEW OP ENDOCRINE FACTORS ASSOCIATED WITH 
CARCINOMA OF THE PROSTATE
Distribution and Incidence. —Cancer of the prostate
is characteristically a disease of men over the age of 40
years; the incidence increasing with advancing age.
37
Joeck reporting in 1940 found no more than 25 cases of 
carcinoma of the prostate in individuals less than 30 
years of age in the world literature. The youngest case 
on record is that of a 6^- year old boy. In 1948 Creevy'*'  ^
referred to the previous literature on carcinoma of the 
prostate. He stated that the recorded incidence varied 
between 14 and 46 percent of all men past the age of 50 
years, that in the United States the estimated number of 
cases at any one time is between 3,000,000 and 8,000,000, 
and that the disease is responsible for five percent of 
all deaths in men past 50 years of age. The United 
States Public Health Service estimates that one man in 
seven past 50 years has the disease .^
47
In 1946 Nesbit and Plumb presented a report on the 
follow-up of 795 patients treated prior to the endocrine 
therapy era. The ages of their patients at the time of 
initial diagnosis varied between thirty-three and eighty- 
nine years with an average of 67.6 years. In the analy-
7
sis of 1000 cases reviewed by Bumpus the average age
was 65 years; the youngest was 42 years. Kimbrough and 
39
Lewis, commenting on the rarity of cases under the age
5.
6.
of 40 years, recently reported two cases; one of the 
patients being 18 years old and the other patient 20 
years of age.
Although racial incidence does not necessarily indi­
cate that hormones are involved in prostatic carcinoma, 
it does suggest that some constitutional or genetic 
factor may be important in prostatic carcinogenesis, and 
certainly such factors may have their influence via the 
endocrine system. In Chinese people cancer of the pros­
tate is a rare tumor. In a series studied by Hu and
Ch’ in there was only one case of cancer of the prostate
27
in 379 carcinomas in Chinese men.
50 51
Ravich * in a survey of 1407 cases requiring 
prostatic surgery found the startling low percentage of
1.8 percent of cancer among 1275 Jewish patients as 
against 20 percent of cancer among non-Jews. This is a 
significant figure in light of Young’ s statement that 
20 percent of all men over 60 have prostatic disease 
and of these 20 percent have cancer. The incidence in 
Negroes Is identical to that in the Caucasian races.®5
To my knowledge there is not a single case reported 
in the literature of carcinoma of the prostate in a 
eunuch or in a true eunuchoid. The criteria for the 
eunuchoid state are the changes in the secondary sexual
7.
organs, and not the fact that the testis are small. This 
is good evidence that carcinoma of the prostate does not 
develop except in the presence of an androgen-producing 
testis.
The total excretion of urinary 17-ketosteroids has 
been determined in cases with prostatic carcinoma and 
compared with that in normal males in a similar age 
group. The results indicated that the total 17-ketoster- 
oid excretion in older men is less than in men between 
the ages of 20 and 40, but that the cases with carcinoma
of the prostate do not differ from control cases of a
17 2ft
similar age group. '* °  As the biochemically active 
urinary androgens decrease there is a progressive in-
14
crease in the incidence of carcinoma of the prostate.
It would seem then either that androgenic compounds 
exert their carcinogenic effects early in life or that a 
lesser degree of androgenic stimulation over a longer 
period of time is the important thing as far as the 
development of prostatic carcinoma Is concerned.
Effects of Castration. —Approximately 80 percent 
of patients with carcinoma of the prostate show clinical
Q
improvement when treated by orchiectomy.0 In the patients 
who respond to treatment there is a decrease in the amount 
of pain, shrinkage of the primary tumor, x-ray evidence
8.
of healing of osseous metastases, a better nutritional 
state and a decrease of the serum acid phosphatase level.
Dean, Woodard and Twombly in an experimental ob­
servation on 27 cases of cancer of the prostate determined 
the precastration and postcastration levels of estrogen 
and 17-ketosteroid excretion. Since castration was not 
thought of as affecting the adrenals, they expected the 
estrogens to remain constant and the 17-ketosteroids to 
fall, thus bringing about a shift in the estrogen-androgen 
ratio toward a higher estrogen and lower androgen level* 
These theoretical changes were not borne out by experi­
mental observations. The estrogens dropped in all but 
one of their patients to about one-half the precastration 
level. The 17-ketosteroids tended to remain the same or, 
as time went on, to rise slightly. Gonadotropins from 
the anterior pituitary showed a definite postcastration 
rise in eleven cases, while in none of the cases was
there a fall in the urinary gonadotropic hormone post-
34
operatively. Scott and Vermuelin, in a similar study, 
obtained comparable results.
Attempts to correlate histological findings in re­
moved testicles with the clinical effect of this surgical 
procedure, in cases of carcinoma of the prostate, have 
been unsuccessful. Angrist and Khoury1 attempted to
9.
estimate the degree of function of the testis by the 
morphological appearance of the seminiferous tubules, of 
the Sertoli cells and of the interstitial tissue. They 
found that neither hyperplasia nor atrophy of the above 
mentioned morphological constituents, singly ,or combined, 
bore any relationship to the presence or absence of 
clinical improvement following the removal of such 
testicles.
The Effects of Estrogens.-- The percentage of patients 
with carcinoma of the prostate showing temporary remission 
of cancer activity after treatment with estrogens alone is
O
about 75 percent. Clinical evidence of response to ther­
apy is the same as in patients treated by orchiectomy.
Occasionally, continued administration produces pain in
34
the breasts and testis.
12
Dean and associates in a study similar to the one 
they did on the precastration and postcastration levels 
of estrogen, gonadotropin and 17-ketosteroid excretion, 
obtained assays on nine men before and after treatment 
with two to five mg* of diethylstilbestrol daily. The 
estrogenic assays on these men averaged 16.6 mouse units 
per twenty-four hours before treatment. After treatment 
this figure rose enormously because a certain amount of
10.
the diethylstilbestrol was excreted In the urine. The 
17-ketosteroids before treatment averaged 8.9 mg. of 
androsterone equivalent per twenty-four hours, but after 
treatment these metabolites fell in every case with the 
average being 5.4 androsterone equivalent. In a group 
of six patients studied for gonadotropic hormone ex­
cretion rate before and after stilbestrol, there was no 
post-treatment increase. Three showed no measurable 
excretion either before or after stilbestrol, while the 
other three, showing small quantities of hormone in the 
urine before the administration of the drug, excreted 
too little to measure after it was started.
Prom the point of view of hormones excreted in the 
urine, therefore, the treatment of prostatic carcinoma 
by orchiectomy differs considerably from treatment with 
stilbestrol. Castration seems to cut estrogenic ex­
cretion in half, tends to raise 17-ketosteroid excretion, 
and to release the pituitary from testicular inhibition 
so that it pours out its gonadotropic hormone in exces­
sive quantities. Diethylstilbestrol raises the estro­
genic excretion and decreases both the 17-ketosteroid ex­
cretion rate and the quantity of gonadotropic hormone in 
the urine.
11
Clarification of the true EBchanlsm by which prostatic 
cancer regresses after castration or the administration of 
stilbestrol must await more detailed analysis of the 
changes produced. Regardless of the contrasting hormonal 
changes, it would seem likely that stilbestrol adminis­
tration to the intact male is not unlike castration, for 
stilbestrol diminishes androgen production by the testicles 
and adrenal glands through the mechanism of reducing lutein­
izing hormone output by the pituitary.3>52,55 Experi­
mental studies suggest that antagonistic actions may exist 
between estrogens and androgens in regard to the pros- 
tate.2 »30»33
Apparently the two methods of treatment complement 
each other. Nesblt and Baum46 in a clinical and statist­
ical study of 1818 cases of prostatic carcinoma demon­
strated that control of carcinoma of the prostate is most 
effectively obtained by the combined employment of castra­
tion and stilbestrol administration.
The cytological changes in the prostatic cancer 
cells following diethylstilbestrol therapy have been in­
tensively studied by Kahle, Schenken and Burns.38' 53 
These observers were able to demonstrate certain regres­
sive changes in the nuclear and cytoplasmic material.
Initially these changes consist of pyknosis of the nuclei 
and vacuolization of the cytoplasm. Later there occurs 
progressive fragmentation and disappearance of nuclear 
material, rupture of cell membranes, loss of cellular 
outline and finally replacement by fibrous stroma, smooth 
muscle and round cells.
Ludford and Brnochowski,41 by investigating the action 
of stilbestrol on ten different transplantable mouse 
tumors in mice of four Inbred strains, were convinced that 
stilbestrol itself is not a mitotic poison such as col­
chicine and sodium cacodylate. Neither in vivo nor in 
vitro did stilbestrol prove to have a mitotic poisoning 
action on the malignant cells.
The fact that recrudescence usually occurs after vary­
ing lengths of time has been adduced by most observers as 
evidence that all cancer cells are not destroyed but that 
some remain dormant until becoming reactivated. In all 
cases in which radical perineal prostatectomy has been 
done for cancer after preoperative administration of estro­
gen, malignant cells have been readily demonstrated in the 
surgical specimens.
The Effects of Androgens. —Huggins'^ and associates, 
Brendler^ and associates and Flocks^® have each reported 
treating three cases of carcinoma of the prostate with
12.
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testosterone propionate intramuscularly for short periods 
of time. Huggins states that his three cases all showed 
an increase in pain at the site of bony metastases. He 
elaborated no further. Two of Flocks' patients had bony 
metastases and both showed clinical deterioration on 
testosterone. The third case showed no effect. Two of 
Brendler’ s cases had metastases and were in relapse; 
they showed clinical signs of improvement as manifested 
by an increase in appetite and weight. Brendler’ s third 
case was unaffected. In both Flocks’ and Brendler’ s 
cases which had metastases there was an increase in the 
level of serum acid phosphatases.
On the basis of these preliminary studies there ap­
pears to be evidence of a pluripotential response of car­
cinoma of the prostate to androgens. The response of 
patients that have had no anti-androgenic treatment is 
most often a worsening of their disease. Flocks’ and 
Brendler’ s cases with metastases differ in that Brendler’s 
cases were in relapse. It can be postulated that the 
patients treated by Brendler had neoplasms that were 
androgen independent and the clinical benefit noted was 
due to the anabolic effects of testosterone. Further 
investigation of the role of androgens in prostatic can­
cer is warranted.
14
Histological studies to demonstrate the effect of 
androgens on carcinoma of the prostate are not in the 
literature. However, Moore and McLellan^ gave an indi­
vidual with the disease 600 mg. of testosterone prop­
ionate over a period of 12 days. The histological ap­
pearance of this cancer was not different from the usual 
carcinoma of the prostate.
The Effects of Other Steroids. —According to the
52
concept of Reifenstein et al, androgen production by 
the adrenals as well as by the testes is under the in­
fluence of the luteinizing hormone (LH). These workers 
demonstrated a decrease in the output of 17-ketosteroids 
following administration of methyl testosterone and 
adduced considerable evidence to support their point of 
view that the decrease depended upon reduction of LH 
output. Methyl testosterone is not excreted as a 
17-ketosteroid due to the stability of the methyl radical 
in the 17-carbon position.36
On first Inspection, there appears to be little 
possibility that Reifenstein*s concept might be utilized 
in the treatment of prostatic carcinoma, for methyl 
testosterone is a potential stimulator of the growth of 
prostatic carcinoma. However, Trunnel and Duffy,
15.
following a similar line of reasoning, felt that progest­
erone, which also decreases LH output in the female,3 
might in the same way decrease androgen production in 
prostatic cancer-bearing males without itself stimulating 
the disease. They treated 15 patients with progesterone 
in doses of 25 to 300 mg. daily. Thirteen of these 15 
patients responded favorably to progesterone administra­
tion; seven of these previously had a spontaneous relapse 
after castration or estrogen therapy. Although progest­
erone appears efficacious, it cannot be recommended in 
preference to castration or to estrogen administration. 
However, for patients in whom the disease has relapsed 
after other forms of treatment, a trial of progesterone 
would appear to be indicated.
Cortisone has been used in some clinics in an at­
tempt to accomplish a ”medical adrenalectomy” through the 
mechanism of “compensatory atrophy” .25,29,55,61 Harrison, 
Thorn and Jenkins24 treated nine patients with cortisone 
in a dosage of 25 to 37 mg. a day for periods of one to 
three months after initial doses of 100 mg. for several 
days. All but one patient had an improved sense of 
well-being and some relief of pain, but there was no 
objective evidence of regression of neoplastic tissue.
In all patients 17-ketosteroid excretion diminished on
16.
this dose of oral cortisone, indicating a degree of adreno­
cortical inhibition. The usual fall was from approximately 
10 mg. to 6 mg. in twenty-four hours on this regimen.
The general consensus is that, although cortisone 
acetate reduces the 17-ketosteroid production and produces 
a sense of euphoria, it does not significantly alter the 
course of prostatic cancer. Cortisone administration to 
the dog is not followed by androgenic effects.29
The Effects of Bilateral Adrenalectomy.--Assuming
that androgens are an activating factor in the regrowth
of prostatic cancer after castration or estrogen therapy,
32
Huggins and Scott attempted the further elimination of 
androgens by total adrenalectomy. Some clinical improve­
ment was observed after this procedure in the one patient 
who survived a significant length of time, 116 days, but 
this was limited because of the inadequacy of the sub­
stitution therapy available at that time (1945). Cox10 
made a similar effort in 1947.
The advent of adequate substitution therapy with 
cortisone has reopened this line of investigation in the
OQ
past two years. Huggins and Bergenstal reported in 
1952 the effects of bilateral adrenalectomy in seven 
cases of prostatic cancer. There was one postoperative
17.
death, and one patient died of a pulmonary embolus 49 
days after adrenalectomy. The period of observation of 
the remaining cases at the time of their report had been 
four to nine months. Objective signs of improvement were: 
decrease in the size of the primary tumor in two of the 
four patients that had large, hard glands, gain in weight 
in all patients, increase hemoglobin concentration in 
five patients, increase in the total number of circulat­
ing erythrocytes in three patients, increase in tbs serum 
total proteins in three patients and the two patients 
who had increased levels of serum acid phosphatase showed 
a decrease. Pain was completely relieved in five cases 
two days after adrenalectomy. They were of the opinion 
that three of the six patients available for study in this 
series had had a clinical remission of the disease of a 
considerable magnitude.
West6** and associates observed the results of the 
procedure in seven cases with prostatic cancer. At the 
time of their report six of the seven patients were dead. 
Pour of six died from their neoplastic disease; two from 
adrenal insufficiency. The postoperative survival period 
averaged 163 days. All seven patients had temporary sub­
jective improvement averaging 83 days. Only two out of
18
the seven had objective signs of improvement. This lasted 
90 and 133 days in the two cases.
Harrison2^ and associates reported on seven cases of 
reactivated carcinoma of the prostate. In addition to the 
objective signs of improvement noted by Huggins in the 
cases that he treated by bilateral adrenalectomy, Harrison 
also noted relief of urinary obstruction, roentgenographic 
evidence of healing of osseous metastases and a decrease in 
the urinary 17-ketosteroid excretion in six cases. A sus­
tained regression for 17 months has been obtained in one 
case.
The apparent subjective and objective improvement of 
patients after total adrenalectomy indicates at least a 
temporary biologic arrest of the progress of cancer of the 
prostate. Available evidence today seems to signify that 
this arrest is accomplished by means of altered metabolic 
processes pursuant to changing of the hormonal environment 
of the neoplastic cell.
Androgen Independence. --As defined by Huggins and 
32
Scott, the androgen independent prostatic carcinomas 
are those in which anti-androgenic therapy fails. Deming15 
demonstrated the phenomenon of androgen independence by 
making serial transplants of prostatic cancer tissue into 
the anterior chamber of the eyes of guinea pigs. Up
19
until the eighth generation the tissue would grow only in 
males. After the eighth generation the tumor had so 
changed its biological properties that it would grow in 
the eyes of females or orchiectomized males. It would 
appear from this study that the prostatic cancer tissue 
employed originally required a stimulus from functioning 
testis for its growth in the anterior chamber of the 
guinea pig’ s eye, but with successive transfers it became 
sufficiently autonomous to grow without tropic stimu­
lation.
Clinically this change in character of prostatic 
cancer tissue has been demonstrated by adrenalectomy in 
previously orchiectomized patients after their prostatic 
cancer had reactivated. Although the 17-ketosteroid 
output in the urine is greatly reduced a second regres­
sion of the tumor has not been noted in some of the 
cases reported that survived for a reasonable length of 
time suggesting that an increased production of adrenal 
androgen was not the cause of the regrowth of the tumor. 
On this evidence it has been postulated tiiat certain 
prostatic cancers become independent of androgen stimu­
lation.
20.
FOLLOWING THE CLINICAL COURSE OF PATIENTS WITH CARCINOMA
OF THE PROSTATE
A. The Serum Acid Phosphatase Test. —Prior to 1935 the
physicians only laboratory aids in following the course
of prostatic cancer were the microscope and X-ray. It
was then discovered that the prostate was rich in an acid
20
phosphatase, most active at a pH of five. Very little
is normally present in the blood, and no excess is found
in early carcinoma of the prostate which is still local- 
P I  22
ized. * When the tumor has extended beyond the cap­
sule, then the amount of serum acid phosphatase shows a 
definite and varying increase in approximately 65 percent 
of cases.57 Excessive phosphatase is readily demonstrable 
in histological sections of the tumor and its metas- 
tases.^®,35 However, the amount of enzyme in prostatic 
carcinoma tissue is less than the amount present in a 
normal gland and the amount found in metastatic lesions 
is less than in the primary tumor. 66
The test is of particular value in corroborating 
clinical and roentgenologic findings. It is of prognostic 
significance, in determining the response to treatment 
and determining when relapse has occurred. Castration 
or estrogen therapy will cause a decrease in the serum 
acid phosphatase, while injection of androgens frequently
results In a further Increase; cortisone administration or 
bilateral adrenalectomy results in a decrease.
The test may fail in anaplastic tumors which elaborate
very little of the enzyme or when blood stream or lymph
IQ
invasion has not progressed sufficiently.
B. Other Objective Evidence. — In addition to the deter­
mination of the serum acid phosphatase level there are 
other objective evidences that are useful in following 
the clinical course of prostatic carcinoma patients. In 
a patient who has obtained a good response to anti-andro­
genic therapy there is noted an improved nutritional state. 
This is manifested by an increase in weight, strength and 
activity. The blood picture shows an increase in hemo­
globin, red cells and total protein.
Soft tissue masses decrease in size and osseous 
metastases show X-ray evidence of healing. With this de­
crease in size of metastases, physical findings such as 
neurological signs due to the metastases improve.
Increased serum alkaline phosphatase occurs in ob­
structive liver disease and with any significant increase 
in osteoblastic activity, such as occurs in Paget's 
disease, healing fractures, or bone reaction to metastatic
22
cancer. Carcinoma of tbs prostate with metastases to tbe 
bone usually sbows both an increase in the serum alkaline 
and acid phosphatase. A remission of prostatic carcinoma 
with bony metastases is accompanied by an increase in the 
level of the serum alkaline phosphatase due to osteoblastic 
activity with healing of the osseous metastases. In car­
cinoma of the prostate without metastases the serum alka­
line phosphatase has no prognostic significance.
An attempt has been made to correlate the clinical
status of prostatic carcinoma patients with their urinary
excretion of 17-ketosteroids. In the patients whose
disease is controlled by estrogens, or estrogens and
orchiectomy, there is a significant, persistent decrease
in tbe urinary excretion of 17-ketosteroids. Orchiectomy
alone results in a temporary decrease but the value soon
returns to normal or slightly higher.12 The attempt has
been made to ascertain a rise in 17-ketosteroid excretion
as a signal of increased adrenal activity and consequent
reactivation of cancer because of escape from hormonal 
24
control. Such a correlation of increased 17-ketosteroid
V \
excretion and coincident reactivation of prostatic cancer 
would be an important observation but so far it has not 
been demonstrated.
Recent experimental investigations of the glycolytic
23.
enzyme, aldolase, has demonstrated that any change in 
prostatic cancer activity is reflected by a prompt fluc­
tuation in the level of serum aldolase. Abnormally high 
concentrations of aldolase are present in the serum of 
60 to 70 percent of patients studied with active, advanced, 
untreated prostatic carcinoma. Following orchiectomy or 
stilbestrol administration the increased serum aldolase 
concentration returns to normal range in 85 to 90 percent 
of the patients studied. Baker4 and associates, therefore, 
believe that serum aldolase is equally as effective in 
indicating activity as is the classically accepted bio­
chemical indicator of advanced prostatic cancer activity, 
namely, serum acid phosphatase. The value of this test 
in cancer of the prostate is yet to be proven; only pre­
liminary investigations have been made.
42
Malcolm and Rusche working with proteolytic enzymes 
and their inhibitors demonstrated that chymotrypsin and 
rennin inhibitors of the serum provide a sensitive method 
for gauging the therapeutic control of neoplasms. In a 
study of six patients with carcinoma of the prostate they 
found a correlation to exist between the levels of these 
two enzymes in the serum and the clinical status of the 
patients. In patients that showed a good response to 
anti-androgenic therapy, chymotrypsin inhibitor tended to
rise and rennin inhibitor fell. In patients showing a 
reactivation of their disease, the serum level of anti- 
rennin rose and antI-chymotrypsin fell. Adenocarcinoma 
of the prostate which is limited to the confines of the 
capsule has not as yet been found to induce an imbalance 
in the enzyme pattern.
Their tentative assumption is that, in some manner, 
chymotrypsin inhibitor reflects the rate of protein de­
gradation while rennin inhibitor seems to be allied with 
protein synthesis. They believe that the degree of con­
trol obtained in prostatic carcinoma following orchiectomy 
or estrogen therapy may be measured objectively by observ­
ing the resulting changes in the concentration of the two 
factors.
OTO INVESTIGATIONS
On the basis of experimental and clinical investi­
gations many urologists believe that relapse in carcinoma 
of the prostate that has been controlled by hormonal 
measures is due to a restimulation of residual cancer by 
some androgenically active substances produced by the 
adrenal glands. Since the number of circulating eosino­
phils fall sharply when the adrenal gland is acutely 
stimulated, it seemed possible that such an increase in
25
adrenal function might be reflected in the eosinophil 
count. The purpose of this investigation was to determine 
whether or not such a change occurred in the circulating 
eosinophils of patients with reactivated carcinoma of the 
prostate. Quantitative eosinophil leucocyte determina­
tions were done in the following groups of patients:
1. Patients with carcinoma of the prostate who were 
controlled by hormonal therapy.
2. Patients with reactivated carcinoma of the 
prostate after a remission induced by anti- 
androgenic measures.
3. Patients with a type of malignancy other than 
carcinoma of the prostate.
Methods. —The"technique employed in counting the 
eosinophil leucocytes was described by T. G. Randolph49 
in 1943. Freely flowing capillary blood was collected 
from a deep puncture in the tip of the finger. The blood 
was mixed in a proportion of 1:20 with a stain composed 
of diluting fluid containing 0.1 percent methylene blue 
and 0.1 percent of phloxine dissolved in an equal part 
of propylene glycol and water. The eosinophil granules 
assume a deep red color and the nucleus a light robin 
egg blue. The remainder of the white blood cells stain 
a light greenish hue. The red blood corpuscles are
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hemolyzed. A sample of the bloodstain mixture was im­
mediately transferred to a counting chamber where the 
main staining occurs in the course of fifteen minutes.
The cells in an entire Spencer counting chamber were enum­
erated and the number obtained multiplied by the factor
11.1 to obtain the number of eosinophils per cu. mm. of 
blood.
Many standard textbooks of clinical pathology and 
hematology present the normal range of eosinophils in 
the circulating blood in health. The range of normal is
4,0
estimated to be 0-400 by Osgood, 50-400 by Todd and 
Sanford58 and 75-300 by Kracke and Parker.4® At the time 
this study was undertaken, 1950, the literature did not 
reveal any significant data regarding the fluctuations 
or diurnal variations of such blood cells in health.
Since that time, however, Bonner5 demonstrated that fast­
ing alone will cause a drop in the eosinophil count. Hal- 
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berg and associates found an average morning drop in 
eosinophils between the hours of 06:30 and 09:30 of from 
430 to 251 per cu. mm. controlled subjects with the count 
returning toward the higher level during midday. They 
found a rough inverse relation between oral temperature 
and the eosinophil level in controlled subjects. Their 
observations failed to show the normal diurnal rhythm in 
patients with Addison’ s disease, bilateral adrenalectomy
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and hypopituitarism. Prom their studies they have con­
cluded that the adrenal control hormones play a part in 
eosinophil level fluctuations in the subject. Fisher and 
Fisher^-5 in 463 observations on 170 subjects found a 
diurnal variation in both fasting and non-fasting indi­
viduals. Of the fasting group, 23 percent showed a drop 
of 40 percent or more in the total circulating eosino­
phils in the forenoon with a rise later in the afternoon. 
The non-fasting subjects demonstrated this phenomenon 
fairly consistently but not to the degree observed in the 
fasting subjects. They concluded that "it would be d iffi­
cult to use this phenomenon as a sensitive indicator of 
pathologic variations” .
The counts for this study were carried out on patients 
being followed in the Urology Division of the Bonfils Tumor 
Clinic of the University of Colorado Medical Center.
Counts taken on patients with types of malignancy other 
than cancer of the prostate were made while the patients 
were hospitalized at Colorado General Hospital or while 
they were being followed in the Surgery Division of the 
Bonfils Tumor clinic. The eosinophil counts were made 
approximately every two months. Due to the fact that some 
patients have to come great distances and make infrequent 
visits to the clinic only one or two counts were made in
some instances. The counts were performed on ambulatory 
patients under basal conditions, without food since break­
fast and resting in the laboratory. The taking of samples 
commenced at approximately 12:00 p.m. This time of day in 
relation to the diurnal fluctuations of the circulating 
eosinophils finds them near their high level of normal.
Table I gives the results of eosinophil leucocyte 
counts, one enumeration, in ten normal young adults. 
Healthy subjects in an age group similar to the usual age
of patients with carcinoma of the prostate could not be 
obtained.
Table II demonstrates counts in two patients with 
three-year cures of cancer of the prostate following 
radical prostatectomy. There is no evidence of disease 
in either patient, therefore I think these counts could 
be considered normals in a healthy older age group.
When surgery for complete removal of the tumor is 
precluded due to local extension or metastases, treatment 
in this clinic consists of transurethral electroresection 
of the prostate for relief of urinary obstruction and 
anti-androgenic therapy— orchiectomy and stilbestrol 5 mg. 
orally, daily. This method of treatment has been followed 
routinely in tnis clinic since Nesbit’s and Baum*s46
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TABLE I
Eosinophil Leucocyte Cotints in Ten 
Healthy Young Adults
Patient Age Count
P .J . 20 143
D.A. 29 275
V.D. 27 199
I.M. 33 353
I.A . 21 198
V.P. 24 246
G.P. 25 253
D.S. 23 289
A.W. 32 165
D.H. 28 246
The average of this group is 237 eosinophils 
per cu. mm. of blood. A variation of from 165 to 
353 eosinophil leucocytes per cu. mm. is observed. 
On the basis of Fisher and Fisher’s work they be­
lieve, for clinical purposes, that a normal range 
of 25 to 300 would be optimal.
TABLE II
Eosinophil Leucocyte Counts in Two Patients 
Apparently Cured by Radical Perineal Prostatectomy
Pt. Age Counts
E.H. 71 154 110 220 220
C.S. 72 166 143 144 121
The counts in these two patients closely 
resemble the counts in the healthy young 
adults•
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report in 1950 indicated that carcinoma of the prostate 
is most effectively controlled by the combined employment 
of castration and stilbestrol administration. When neces­
sary a punch biopsy is done to establish the diagnosis.
All of the cases of carcinoma of the prostate to be pre­
sented subsequently had had a histological diagnosis of 
their disease and clinical management has been carried 
out as indicated above.
Eight cases of carcinoma of the prostate were ob­
served during reactivation of their disease. Six of 
these cases had metastases. All of these patients showed 
some evidence of clinical deterioration. (See Table III)
With the exception of three observations in different 
patients, all of the eosinophil leucocyte counts in the 
patients with reactivated prostatic carcinoma are below 
100 per cu. mm. of blood. The normal range of eosinophils 
in the circulating blood is so great that the arbitrary 
value of 100 has been chosen for purposes of comparison 
between the different groups of patients in this study.
Insufficient numbers of patients were available for 
study to warrant a vigorous statistical evaluation of the 
results. It is obvious, however, that if a depression In 
eosinophil count is to be of clinical value in following
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TABLE III
Eosinophil Counts in 8 Patients with Cancer of the 
Prostate who were Relapsing after Previously 
being Controlled by Orchiectomy and Stilbestrol.
Pt. Age Eosinophil
Counts Comments
J 67 99 110 99 Fullblown regression during entire 
period of time covered by counts.
D.W. 79 66 77 Died five months after diagnosis, 
two months after last count.
C «P • 86 55 44 88 
77 99
Relapse only apparent at time of 
last visit to the clinic.
J • £ • 66 55 77 99 Symptoms of relapse at time of 
last count.
A •? • 82 55 Died tnree months after count with' 
metastases to penis.
J»C • 81 88 0 22 Pathological fracture of the left 
kip.
J • S • 75 165 88 Confined to bed. No known metas­
tases .
L.E. r 57 T.98 Very anaplastic tumor showing 
rapid growth locally. No known 
metastases.
It is noted that the counts in this group have a 
tendency to be consistently lower than those seen in healthy 
individuals. The average is 80.5 eosinophil leucocytes per 
cu. mm. of blood.
the course of prostatic carcinoma it must occur with regu­
larity and be of considerable magnitude in patients who 
have reactivated disease. To determine if there was a dif­
ference in the eosinophil leucocyte count between patients 
with carcinoma of the prostate showing reactivation of their 
disease and patients that were controlled by anti-androgenic 
tuerapy, serial quantitative eosinophil leucocyte determina­
tions were done on a group of 27 patients exhibiting a good 
response to stilbestrol and orchiectomy. Only three of this 
group of 27 patients had metastases. (See Table IV)
The three cases with metastases were well controlled 
by anti-androgenic therapy. With the exception of one 
determination all of the counts in these three patients 
were above 100 eosinophil leucocytes per cu. mm. of blood, 
-til© last eight subjects listed in this group had counts 
that were all below 100. The determinations in this group 
of eight patients demonstrate the presence of a great 
degree of overlap in the eosinophil counts between the 
reactivated and the controlled group of cases. The 
patients with low counts showed no evidence of a reactiva­
tion of their disease.
Because of the marked degree of overlap noted be­
tween the reactivated and controlled cases this labora­
tory procedure does not seem to be very promising as a
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TABLE IV
Eosinophil Enumerations in 27 Patients with Carcinoma of 
the Prostate V3ho ware Well-controlled on Therapy Con­
sisting of Orchiectomy and Stilbestrol, 5 Mg. Daily.
Pt. Age Eosinophil Counts 
8 week Intervals Comment
C.B. 73 203 198 144 198 209
J.G . 67 355 308 275 209 132 275
F.H. 75 264 220 154 133 198
J.R. 67 133 220 164 110 200
M.S. 66 “297 198 143
B.V. 70 191 132 110 llO
M.M. 77 154 99 110
H.M. 75 210 143 110 154 210
W.N. 59 170 132 110 148
H.D. 75 66 66 121
A.K. 69 99 88 99 110 154
J.R. 61 33 44 33 144
R.M. 67 154 44 99
J 73 154
S. P. 74 152 110 154 leukotomy for pain due to 
metastases 3 yrs. before 
counts.
P.B. 70 198 121 Metastatic inguinal nodes 
disappeared on treatment.
H.K. 67 112 99 Had metastases to bone.
M.P. r 74 110 Stilbestrol only.
A.G. 71 142 Stilbestrol only.
J »D. 84 0 No treatment.
A.B. 84 55 44 44 55 99
E#S# 82 66 35 77 77 55 '
A .i . 81 99 66 88 77
"P.O. 91 88 44 44 0 99
B.M. 71 '44 55
T.S. 74 99
1J.M. 79 99
The average eosinophil leucocyte count in this group is
124.8 per cu. mm. of blood. The last 8 subjects listed in the 
table had counts that were consistently below 100. In addition, 
six others had a count of less than 100 at one or more times.
tool for following reactivation of cancer of the prostate. 
To see if the suggestively low counts in the reactivated 
group were unique for cancer of the prostate, patients 
with other metastatic carcinoma of other organs were in­
vestigated. Table V illustrates a group of patients 
with various types of metastatic malignancies other than 
carcinoma of the prostate. Many of these patients were 
nearing terminus. Although the number of determinations 
are inadequate it would appear that the eosinophil counts 
are lower than the counts of the controls or the patients 
with prostatic carcinoma controlled by hormone therapy.
When the results of the eosinophil leucocyte deter­
minations in the patients with metastatic cancer other 
than cancer of the prostate are compared to the results 
obtained in the patients with reactivated prostatic car­
cinoma, it is observed that the two groups have eosino­
phil counts that are very similar. This observation sug­
gests that the low counts in both groups are due to 
adrenal hyperactivity caused by "non-specific” stress and 
indicates that a low eosinophil count is not specific in 
reactivated cancer of the prostate. The comparison of 
the results in the three groups of patients studied in­
dicates that the absolute level of circulating eosinophils 
is not a good gauge of prostatic cancer activity, and that
35.
TABLE V
Eosinophil Counts in 20 Patients with Metastatic 
Malignancies Other Than Cancer of the Prostate
Pt. Age Eosinophil
Counts Diagnosis
E .E.
P.E.
71 71 60 44
70
75
99 110
Cancer of bladder pre-and postopera­
tive.
Cancer of stomach— inoperable
A.S, 77 Cancer of kidney--before surgery*
V~l rx -VI "1 1 __r J  - — - - , £■« » i I , m m I Aari I j /  • , IF.D. 59
68
11 55 
1SS
- -----—------------ - j - - ^  _ . . _ — ~
Cancer of lung— inoperable. 
Cancer or stomach— t '•inoperable,65" TFT 143 Gancer of cervix— inoperable 
Cancer of cervix—recurrent.J.P,
K.L.
8T
51"
71
IBT
888 165 Cancer of cervix—recurrent
I T L’ancer or cervix--inoperable.R.W.
7 ^ ;
52 99 Cancer of cervix— recurrent
62"
4T
Expired two days after count.
H.M. 88 Cancer of cervix— inoperable,60
76
99 66 Metastatic cancer of breast.
R.M. 88 Metastatic cancer of breast
i #rx#
A.F.
65
48
62
66 
187 144
Metastatic cancer of breast. 
Metastatic cancer of breast,
66 88 Breast cancer— postmastectomv
n a -P U ~___2~ — 1' ' 1 -45
72"
10_________
32 110 99
Cancer of breast— DreonftT>fl Hira
f ! Q n A A V >  v n '"! ' ^
7ST
77
Cancer of breast— one year cure.
6T 55 Metastatic cancer of breast.
Counts in this group of patients have a tendency to
be low when compared to the counts in the patients with
cancer of the prostate who were controlled by orchiectomy
and stilbestrol. The average count is 88.1. Sixteen had
at least one count of less than 100 eosinophil leucocytes 
per cu. mm. of blood.
quantitative eosinophil determinations are of no value in 
following the clinical course of patients with carcinoma 
of the prostate.
SUMMARY AND CONCLUSIONS
The history of the development of hormone therapy 
of carcinoma of the prostate has been reviewed. Endocrine 
factors associated with cancer of the prostate and methods 
of following the clinical course of patients with the 
disease have been presented.
A quantitative determination of the circulating 
eosinophil leucocytes has been done in a group of 55 
patients with carcinoma. Of these patients 35 had carcin­
oma of the prostate. Twenty-seven of these 35 patients 
were controlled by anti-androgenic therapy and the remain­
ing eight cases of cancer of the prostate were in relapse 
after previously being controlled by anti-androgenic 
measures. The other 20 cancer patients in which counts 
were done had a metastatic malignancy of a type other 
than cancer of the prostate. An attempt was made to cor­
relate the clinical status of each patient with that 
patient’ s eosinophil counts.
The arbitrary value of 100 eosinophil leucocytes 
per cu. mm. of blood has been chosen for a basis of com-
37.
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parison among the controlled cases, the reactivated cases 
and the cases with other rretastatic malignancies. The 
average eosinophil count in the group of 27 prostatic 
carcinoma patients controlled by anti-androgenic therapy 
was 124.8. In this group there were eight patients who 
had eosinophil determinations that were in every instance 
below 100 per cu. mm. of blood. In the eight patients 
showing reactivation of their prostatic cancer, 20 eosino­
phil determinations were done. The results were above 
100 in only three determinations. The average in this 
group was 80.5 eosinophil leucocyte per cu. 33m. of blood. 
The eosinophil determinations in the group of 20 patients 
with a metastatic malignancy other than prostatic cancer 
averaged 88.1. There were 16 of these patients that had 
one or more counts below 100.
The great degree of overlap noted in the counts in 
the three groups of cases, a small magnitude of the re­
duction of the eosinophil counts in the reactivated cases 
(approximately 30 percent) and the similarity of the 
counts in the group with reactivated prostatic cancer and 
the group with other types of metastatic malignancies 
indicate that the eosinophil leucocyte count is probably 
not a reliable method of following the clinical course of 
carcinoma of the prostate.
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Ihen this study was undertaken in 1950 the exact 
relationship of the circulating eosinophils to the adrenal 
gland was not fully appreciated. Because the administra­
tion of gluco-corticoids or of ACTH to individuals with 
functional adrenals resulted in a decrease in the number 
of circulating eosinophils, it was hoped by many that the 
number of circulating eosinophils might be an accurate re­
flection of adrenal function at all times. Since that time 
most investigators have come to feel that such is not the 
case, except possibly that very low eosinophil counts are 
very frequently encountered in patients during periods of 
known adrenal hyperfunction such as occurs in the post­
operative period and at other times of severe stress. Prom 
this study it would appear that cancer patients undergoing 
relapse after previously being controlled by hormonal or 
surgical therapy exhibit a low eosinophil count. This ob­
servation might suggest that a depressed eosinophil count 
is an indication of adrenal response to ’’non-specific” 
stres3 rather than adrenal hyperfunction with increased 
androgen stimulation to the tumor. This supposition is 
strengthened by the observation that the eosinophil count 
is consistently low in the group of patients nearing 
terminus with metastatic malignancies other than carcinoma 
of the prostate.
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Prom this review and study it appears to me that if 
continuing progress is to be made in the investigation and 
treatment of prostatic cancer, the exact role of androgens 
in the induction of cancer or the maintenance of cancer 
growth must be ascertained. Emphasis must be placed on the 
necessity of classifying prostatic cancers according to 
their biological properties before drawing conclusions as 
to the effectiveness of different modes of therapy. If 
androgen dependence is all-important, other means of 
neutralizing or eliminating androgens must be explored.
If other factors exist, these in turn must be investigated.
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